Kling Biotherapeutics to Present Key Applications for its Primary B-Cell Immortalization, Screening and Antibody Optimization Platform Technologies at PEGS Europe

• Kling-Select is a uniquely promising approach to identifying novel targets and therapeutic antibodies from human and animal sources
• Kling-Evolve enables highly rapid selection of effective neutralizing antibodies against viral escape variants

Amsterdam, NLD – 31 October 2024 – Kling Biotherapeutics (“Kling” or “the Company”), a biotech company developing antibody-based drugs for cancer and infectious diseases, today announces that it will be presenting findings on its proprietary primary B-cell selection and evolution platform technologies, Kling-Select and Kling-Evolve at the Annual Protein & Antibody Engineering Summit (PEGS) Europe, held in Barcelona, Spain from 5-7 November 2024.

Poster one entitled ‘Highly efficient capture of circulating and tissue-infiltrating B cell repertoires from multiple species: Kling-Select,’ describes advances in Kling-Select, a proprietary B-cell immortalization platform developed to efficiently capture and screen B cells demonstrating its promise as an approach to the identification of both valuable new targets and therapeutic antibodies. Kling-Select is applied for the immortalization of B cells derived from human and animal sources such as camelid, rabbit, mouse, and non-human primates. The poster also highlights advances in the optimization of the fully integrated workflow allowing the discovery of functional monoclonal antibodies from primary B cells in as little as three weeks.

Poster two entitled ‘Kling-Evolve as a tool for rapid response to emerging variants and pandemic preparedness: directed evolution of variant-specific antibody from immortalized B cells,’ details the Kling-Evolve platform which enables the rapid ex vivo maturation of immortalized human B cells to identify neutralizing antibodies against escape variants. Kling-Evolve poses the potential for rapid development of countermeasures to combat and pre-emptively address evolving viruses amidst emerging pandemic threats.

Michael Koslowski, Chief Executive Officer at Kling Biotherapeutics, said: “Our technology is a powerful platform which is clinically validated, having been used to discover the fully human Respiratory Syncytial Virus (RSV) neutralizing antibody nirsevimab (Beyfortus™ – AstraZeneca / Sanofi). By using an ‘effective antibody first’ discovery approach, Kling’s platform technologies enable the discovery of relevant, completely novel antigen targets applicable to cancer as well as infectious diseases. Kling is well poised to develop next-generation antibody-based therapeutics to bring new, highly targeted treatments to cancer patients and address rising global concerns of the speed of response to emerging pandemic threats.”

Details of the poster presentations are as follows:

Poster Title: Highly efficient capture of circulating and tissue-infiltrating B cell repertoires from multiple species: Kling-Select

Presenter: Casper Marsman, Senior Scientist – B Cell Platform Lead, Kling Biotherapeutics

Presentation Number: A073

Poster Title: Kling-Evolve as a tool for rapid response to emerging variants and pandemic preparedness: directed evolution of variant-specific antibody from immortalized B cells

Presenter: Alessandra Villa, Director of Discovery Platforms, Kling Biotherapeutics

Presentation Number: A074

Posters will be displayed in the Exhibit Hall at the following dates and times:

Tuesday, 5 November from 10:30 – 19:35 CET

Wednesday, 6 November from 10:30 -17:15 CET

Thursday, 7 November from 10:00 – 13:55 CET